farnesol and Bone Cancer

farnesol has been researched along with Bone Cancer in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (50.00)	29.6817
2010's	1 (50.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Cheng, HL; Hsieh, MJ; Lin, CW; Lu, KH; Yang, JS; Yang, SF	1
Arrich, F; Berger, W; Elbling, L; Heffeter, P; Kotz, R; Kubista, B; Micksche, M; Scotlandi, K; Sevelda, F; Sutterlüty, H; Toma, C; Trieb, K	1

Other Studies

2 other study(ies) available for farnesol and Bone Cancer

Article	Year
Zoledronate blocks geranylgeranylation not farnesylation to suppress human osteosarcoma U2OS cells metastasis by EMT via Rho A activation and FAK-inhibited JNK and p38 pathways. Oncotarget, 2016, Mar-01, Volume: 7, Issue:9 Topics: Biological Transport; Bone Density Conservation Agents; Bone Neoplasms; Cadherins; cdc42 GTP-Binding Protein; Cell Line, Tumor; Cell Movement; Cell Survival; Diphosphonates; Diterpenes; Epithelial-Mesenchymal Transition; Farnesol; Focal Adhesion Kinase 1; Focal Adhesion Protein-Tyrosine Kinases; Humans; Imidazoles; JNK Mitogen-Activated Protein Kinases; MAP Kinase Signaling System; Neoplasm Invasiveness; Nuclear Proteins; Osteoporosis; Osteosarcoma; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Prenylation; Proto-Oncogene Proteins pp60(c-src); rho-Associated Kinases; Snail Family Transcription Factors; Twist-Related Protein 1; Zoledronic Acid	2016
Anticancer effects of zoledronic acid against human osteosarcoma cells. Journal of orthopaedic research : official publication of the Orthopaedic Research Society, 2006, Volume: 24, Issue:6 Topics: Actin Cytoskeleton; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bone Density Conservation Agents; Bone Neoplasms; Cell Cycle; Cell Line, Tumor; Cyclin D; Cyclin E; Cyclins; Diphosphonates; DNA; DNA Replication; Dose-Response Relationship, Drug; Drug Combinations; Drug Screening Assays, Antitumor; Farnesol; Humans; Imidazoles; Osteosarcoma; Protein Prenylation; Terpenes; Zoledronic Acid	2006

Article

Year

Zoledronate blocks geranylgeranylation not farnesylation to suppress human osteosarcoma U2OS cells metastasis by EMT via Rho A activation and FAK-inhibited JNK and p38 pathways.

Oncotarget, 2016, Mar-01, Volume: 7, Issue:9

Topics: Biological Transport; Bone Density Conservation Agents; Bone Neoplasms; Cadherins; cdc42 GTP-Binding Protein; Cell Line, Tumor; Cell Movement; Cell Survival; Diphosphonates; Diterpenes; Epithelial-Mesenchymal Transition; Farnesol; Focal Adhesion Kinase 1; Focal Adhesion Protein-Tyrosine Kinases; Humans; Imidazoles; JNK Mitogen-Activated Protein Kinases; MAP Kinase Signaling System; Neoplasm Invasiveness; Nuclear Proteins; Osteoporosis; Osteosarcoma; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Prenylation; Proto-Oncogene Proteins pp60(c-src); rho-Associated Kinases; Snail Family Transcription Factors; Twist-Related Protein 1; Zoledronic Acid

2016

Anticancer effects of zoledronic acid against human osteosarcoma cells.

Journal of orthopaedic research : official publication of the Orthopaedic Research Society, 2006, Volume: 24, Issue:6

Topics: Actin Cytoskeleton; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bone Density Conservation Agents; Bone Neoplasms; Cell Cycle; Cell Line, Tumor; Cyclin D; Cyclin E; Cyclins; Diphosphonates; DNA; DNA Replication; Dose-Response Relationship, Drug; Drug Combinations; Drug Screening Assays, Antitumor; Farnesol; Humans; Imidazoles; Osteosarcoma; Protein Prenylation; Terpenes; Zoledronic Acid

2006